Oric Pharmaceuticals
ORIC
82 hedge funds and large institutions have $874M invested in Oric Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 6 closing their positions.
164% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 14
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
8% more funds holding
Funds holding: 76 → 82 (+6)
6.36% more ownership
Funds ownership: 90.88% → 97.24% (+6.4%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
21% less capital invested
Capital invested by funds: $1.1B → $874M (-$230M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$40.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$31.8M |
| 3 |
Jennison Associates
New York
|
+$19.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$18.5M |
| 2 |
EC
Euclidean Capital
New York
|
-$12.8M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$8.56M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$2.27M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.37M |
ORIC Hedge Fund Activity: Q1 2021 in Review
82 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2021, worth a combined $874M — down 21% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ORIC positions and 6 closed out — a net gain of 6 holders — while 37 added to existing stakes and 14 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $40.6M. The largest seller was OrbiMed, cutting an estimated $18.5M.
- 82 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2021, up from 76 in Q4 2020.
- Funds reported $874M of Oric Pharmaceuticals stock for Q1 2021, down 21% quarter-over-quarter.
- 12 funds opened new Oric Pharmaceuticals positions in Q1 2021 and 6 closed out, a net change of +6 holders.
- The largest Oric Pharmaceuticals buyer in Q1 2021 was Point72 Asset Management, an estimated $40.6M added.
- The largest Oric Pharmaceuticals seller in Q1 2021 was OrbiMed, an estimated $18.5M sold.
Based on aggregated 13F filings for Q1 2021.